MedTrace Logo

Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)

NCT04470622 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-03-02

Study results available
· View outcomes & findings →

Summary

The study will evaluate the efficacy and safety of aprepitant injectable emulsion added to standard of care for hospitalized patients with COVID-19.

Conditions

Interventions

DRUG

Aprepitant injectable emulsion

Aprepitant injectable emulsion, once daily (QD) for 14 days.

DRUG

Saline Placebo

Saline Placebo, once daily (QD) for 14 days.

Sponsors & Collaborators

  • Heron Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-20
Primary Completion
2021-04-09
Completion
2021-06-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04470622 on ClinicalTrials.gov